146 related articles for article (PubMed ID: 27467962)
1. Combating rituximab resistance by inducing ceramide/lysosome-involved cell death through initiation of CD20-TNFR1 co-localization.
Zhang F; Yang J; Li H; Liu M; Zhang J; Zhao L; Wang L; LingHu R; Feng F; Gao X; Dong B; Liu X; Zi J; Zhang W; Hu Y; Pan J; Tian L; Hu Y; Han Z; Zhang H; Wang X; Zhao L
Oncoimmunology; 2016 May; 5(5):e1143995. PubMed ID: 27467962
[TBL] [Abstract][Full Text] [Related]
2. CD20/TNFR1 dual-targeting antibody enhances lysosome rupture-mediated cell death in B cell lymphoma.
Kim JR; Lee D; Kim Y; Kim JY
Cancer Immunol Immunother; 2023 Jun; 72(6):1567-1580. PubMed ID: 36534148
[TBL] [Abstract][Full Text] [Related]
3. Ceramide participates in lysosome-mediated cell death induced by type II anti-CD20 monoclonal antibodies.
Liu Y; Shu L; Wu J
Leuk Lymphoma; 2015 Jun; 56(6):1863-8. PubMed ID: 25393677
[TBL] [Abstract][Full Text] [Related]
4. [Ceramide participates in cell programmed death induced by Type II anti-CD20 mAb].
Huang Y; Wu S; Zhang Y; Zi Y; Yang M; Guo Y; Zhang L; Wang L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 Dec; 40(12):1292-7. PubMed ID: 26739069
[TBL] [Abstract][Full Text] [Related]
5. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL.
Awasthi A; Ayello J; Van de Ven C; Elmacken M; Sabulski A; Barth MJ; Czuczman MS; Islam H; Klein C; Cairo MS
Br J Haematol; 2015 Dec; 171(5):763-75. PubMed ID: 26471982
[TBL] [Abstract][Full Text] [Related]
6. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
[TBL] [Abstract][Full Text] [Related]
7. Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster.
Li H; Zhang G; Jiang C; Zhang F; Ke C; Zhao H; Sun Y; Zhao M; Chen D; Zhu X; Zhang L; Li B; Dai J; Li W
Oncotarget; 2015 Sep; 6(27):24192-204. PubMed ID: 26284588
[TBL] [Abstract][Full Text] [Related]
8. Type II anti-CD20 mAb-induced lysosome mediated cell death is mediated through a ceramide-dependent pathway.
Ren H; Zhang C; Su L; Bi X; Wang C; Wang L; Wu B
Biochem Biophys Res Commun; 2015 Feb; 457(4):572-7. PubMed ID: 25603047
[TBL] [Abstract][Full Text] [Related]
9. Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma
Chu Y; Yahr A; Huang B; Ayello J; Barth M; S Cairo M
Oncoimmunology; 2017; 6(9):e1341031. PubMed ID: 28932644
[TBL] [Abstract][Full Text] [Related]
10. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
11. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of Rituximab-induced cell death by the physical association of CD20 with CD40 molecules on the cell surface.
Al-Zoobi L; Salti S; Colavecchio A; Jundi M; Nadiri A; Hassan GS; El-Gabalawy H; Mourad W
Int Immunol; 2014 Aug; 26(8):451-65. PubMed ID: 24894009
[TBL] [Abstract][Full Text] [Related]
13. Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis.
Stel AJ; Ten Cate B; Jacobs S; Kok JW; Spierings DC; Dondorff M; Helfrich W; Kluin-Nelemans HC; de Leij LF; Withoff S; Kroesen BJ
J Immunol; 2007 Feb; 178(4):2287-95. PubMed ID: 17277134
[TBL] [Abstract][Full Text] [Related]
14. Genetic and Epigenetic Modulation of CD20 Expression in B-Cell Malignancies: Molecular Mechanisms and Significance to Rituximab Resistance.
Tomita A
J Clin Exp Hematop; 2016; 56(2):89-99. PubMed ID: 27980307
[TBL] [Abstract][Full Text] [Related]
15. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity.
van Meerten T; van Rijn RS; Hol S; Hagenbeek A; Ebeling SB
Clin Cancer Res; 2006 Jul; 12(13):4027-35. PubMed ID: 16818702
[TBL] [Abstract][Full Text] [Related]
16. Dysregulation of the cell survival/anti-apoptotic NF-kappaB pathway by the novel humanized BM-ca anti-CD20 mAb: implication in chemosensitization.
Vega MI; Martínez-Paniagua M; Huerta-Yepez S; González-Bonilla C; Uematsu N; Bonavida B
Int J Oncol; 2009 Dec; 35(6):1289-96. PubMed ID: 19885551
[TBL] [Abstract][Full Text] [Related]
17. Unexpected cross-reactivity of anti-cathepsin B antibodies leads to uncertainties regarding the mechanism of action of anti-CD20 monoclonal antibody GA101.
Chien WW; Niogret C; Jugé R; Lionnard L; Cornut-Thibaut A; Kucharczak J; Savina A; Salles G; Aouacheria A
Leuk Res; 2017 Apr; 55():41-48. PubMed ID: 28122282
[TBL] [Abstract][Full Text] [Related]
18. Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity.
Li HF; Wu C; Chen T; Zhang G; Zhao H; Ke CH; Xu Z
Int J Nanomedicine; 2015; 10():4783-96. PubMed ID: 26257518
[TBL] [Abstract][Full Text] [Related]
19. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.
Jazirehi AR; Vega MI; Bonavida B
Cancer Res; 2007 Feb; 67(3):1270-81. PubMed ID: 17283164
[TBL] [Abstract][Full Text] [Related]
20. Obinutuzumab for B-cell malignancies.
Owen CJ; Stewart DA
Expert Opin Biol Ther; 2014 Aug; 14(8):1197-205. PubMed ID: 24856933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
